(Q48415690)

English

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

scientific article published on 21 September 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. (English)

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

immunosuppression

1 reference

based on heuristic

inferred from title

author name string

Jason Ramtahal

1

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

Anu Jacob

2

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

Kumar Das

3

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

Mike Boggild

4

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

publication date

21 September 2006

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

Journal of Neurology

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

253

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

1160-1164

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

9

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

https://scigraph.springernature.com/pub.10.1007/s00415-006-0178-z

0 references

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0178-Z

21 January 2018

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

https://pubmed.ncbi.nlm.nih.gov/16990994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16990994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta

1 reference

https://pubmed.ncbi.nlm.nih.gov/16990994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16990994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/16990994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16990994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16990994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/16990994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00415-006-0178-Z

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/16990994

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48415690&oldid=1397944515"